Equip

Main information

  • Trade name:
  • Equip Rotavirus Emulsion for Injection for Horses
  • Pharmaceutical form:
  • Suspension for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Equip Rotavirus Emulsion for Injection for Horses
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Equine rotavirus vaccine
  • Therapeutic area:
  • Horses Females

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0241/001
  • Authorization date:
  • 21-12-2011
  • EU code:
  • UK/V/0241/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:April2012

AN:01961/2011

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

EquipRotavirusemulsionforinjectionforhorses

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Qualitativecomposition

EquineRotavirusvaccine(inactivated).

Quantitativecomposition

ActiveSubstances: Per1mldose

InactivatedEquineRotavirusH2strainRP>1.0*

(7.4x10 6

to7.4x10 7

FAID

*Productisblendedbasedonpre-inactivationtitrebuttheblendedand

finishedproductmusthavearelativepotencyofatleast1.0.

Adjuvants: Per1mldose

SPOilAdjuvant:

PluronicL121 1mg

Squalane 2mg

Tween80(Polysorbate80) 0.16mg

PhosphateBufferedSaline to0.05ml

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Emulsionforinjection

4. CLINICALPARTICULARS

4.1 TargetSpecies

Horses(pregnantmares)

4.2 Indicationsforusespecifyingthetargetspecies

Forvaccinationofpregnantmarestoprovidepassivetransferof

antibodiestofoalstoreducetheriskofdiarrhoeacausedby

EquineRotavirusH2serotype.

Maresareabletotransferthepassiveimmunitytothefoals4

weeksafterthethirdvaccination.Foalsofthevaccinatedmares

showanincreaseinantibodiesagainstEquineRotavirusfor

approximatelysixtydays.

Revised:April2012

AN:01961/2011

4.3 Contraindications

Donotuseinunhealthyanimals.

4.4 Specialwarnings

Useofthisvaccineinamarecanonlyaidthecontrolofdiarrhoea

associatedwithrotavirusinitsfoalwhenthefoalreceivesan

adequatequantityofcolostrum,shortlyafterbirth.Boththemare’s

abilitytorespondbytheproductionofantibodiesincolostrumand

theabilityofthefoaltoingestandabsorbthatcolostrumis

requiredforthevaccinetohaveaneffect.

4.5 Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

None.

ii. Specialprecautionstobetakenbythepersonadministering

theveterinarymedicinalproducttoanimals

Incaseofaccidentalself-injection/ingestion/spillageonto

skin,seekmedicaladviceimmediatelyandshowthe

packageinsertorlabeltothephysician.

iii. Otherprecautions

EquipRotavirusdoesnothaveanyimpactonthe

environment.

4.6 Adversereactions(frequencyandseriousness)

Maresmaydevelopasmallvisiblesofttofirmswelling(<3.5x

<2.5cm)lastingforgenerallyonlytwodays.Theswellingmaybe

painfulfor1-2days.Somemaresmayalsodevelopa1ºC

transienttemperaturerise,whichmaylastforupto2days.

4.7 Inmostcasesthesesmallandtransientinjectionsite

reactionsresolvewithnoneedfortreatment.Useduring

pregnancy,lactationorlay

Tobeusedduringpregnancy.

4.8 Interactionswithothermedicinalproductsandotherformsof

interaction

Noinformationisavailableonthecompatibilityofthisvaccinewith

anyother.

Revised:April2012

AN:01961/2011

Thereforethesafetyandefficacyofthisproductwhenusedwith

anyother(eitherwhenusedonthesamedayoratdifferenttimes)

hasnotbeendemonstrated.

4.9 Amountstobeadministeredandadministrationroute

1.0mldosepermaretobeadministeredbydeepintramuscular

injection.

VaccinationSchedule

Pregnantmaresshouldbegiventhreedosesofvaccineconsisting

ofasingle1mldoseadministeredatthe8th,9thand10thmonth

ofeachpregnancy.

4.10Overdose(symptoms,emergencyprocedures,antidotes),if

necessary

Adverseeventsobservedafteradministrationofadoubledoseare

similartothosefollowingadministrationofasingledoseaslisted

inSection4.6.

4.11Withdrawalperiod(s)

Zerodays.

5. IMMUNOLOGICALPROPERTIES

Tostimulateactiveimmunityinpregnantmaresinordertoprovide

passiveimmunitytotheirfoalsasanaidinthecontrolofdiarrhoea

associatedwithequinerotavirusinfection

ATCVetCode:QI05AA09

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

HEPESDiluent:

Eagle’sEarle’sMEMgrowthmedium

HEPESacid

Sodiumhydrogencarbonate

Waterforinjection

Hydrochloricacid

Sodiumhydroxide

6.2 Incompatibilities

Donotmixwithanyothervaccine/immunologicalproduct.

Revised:April2012

AN:01961/2011

6.3 Shelflife

12months.

6.4 Specialprecautionsforstorage

Storeandtransportrefrigerated(2°C-8°C).

Protectfromlight.

Donotfreeze.

6.5 Natureandcompositionofimmediatepackaging

Container:Sterilesingle-usepolypropylenesyringes(Ph.Eur.

3.2.8)containingonedoseeach,andclosedwithrubbertips(Ph.

Eur.3.2.9).

Syringesaresuppliedinpacksof3,10,20and40units.Notall

packsizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinary

medicinalproductorwastematerialsderivedfromtheuseof

suchproducts

Anyunusedveterinarymedicinalproductorwastematerials

derivedfromsuchveterinarymedicinalproductsshouldbe

disposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

PfizerLtd

RamsgateRoad

Sandwich

Kent

CT139NJ

8. MARKETINGAUTHORISATIONNUMBERS

Vm 00057/4310

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHE

AUTHORISATION

Date:05September2008

10. DATEOFREVISIONOFTHETEXT

Date:April2012

22-10-2018

October 22, 2018: Medical Equipment Company Agrees to Pay $5.25 Million to Resolve Allegations of Fraudulent Claims for Compounded Medical Creams

October 22, 2018: Medical Equipment Company Agrees to Pay $5.25 Million to Resolve Allegations of Fraudulent Claims for Compounded Medical Creams

October 22, 2018: Medical Equipment Company Agrees to Pay $5.25 Million to Resolve Allegations of Fraudulent Claims for Compounded Medical Creams

FDA - U.S. Food and Drug Administration

10-10-2018

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

The health risks associated with exposure to artificial UV radiation from tanning booths have been well established for many years now. ANSES points out that recent data on the subject support previous assessments: there is a proven cancer risk associated with UV radiation from artificial tanning equipment. The Agency therefore recommends that the public authorities take the necessary steps to prevent people from being exposed to artificial UV radiation from tanning booths used for cosmetic purposes.

France - Agence Nationale du Médicament Vétérinaire

9-10-2018

Ukrop’s Homestyle Foods, LLC Announces Recalls Because of Possible Health Risk

Ukrop’s Homestyle Foods, LLC Announces Recalls Because of Possible Health Risk

Johnston County Hams’ country ham was recalled due to its potential for contamination with Listeria monocytogenes; therefore, Ukrop’s made the decision that any products that contained country ham or came into contact with equipment used to process the country ham are being recalled due to the potential to be contaminated with Listeria monocytogenes.

FDA - U.S. Food and Drug Administration

19-7-2018

H-E-B Voluntarily Issues Recall Two Variety Packs of Creamy Creations Ice Creams and Sherbets in 3-Ounce Cups Recalled due to Broken Metal in Processing Equipment

H-E-B Voluntarily Issues Recall Two Variety Packs of Creamy Creations Ice Creams and Sherbets in 3-Ounce Cups Recalled due to Broken Metal in Processing Equipment

H-E-B is voluntarily issuing a recall for two variety packs of Creamy Creations ice cream and sherbets in 3-ounce cups due to broken metal found in processing equipment during routine maintenance. The potentially affected products were distributed only to H-E-B stores in Texas. Please note, the product was not distributed to the Houston area or Mexico.

FDA - U.S. Food and Drug Administration

18-7-2018

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

In a context where prevention of ambient air pollution is a real public health issue, questions are regularly asked about the value of recommending that the population wear personal protective equipment. This led ANSES to assess the potential health benefits of wearing "anti-pollution" masks. Its expert appraisal revealed a lack of data demonstrating a health benefit. To reduce the health impacts associated with ambient air pollution, the Agency reiterates the importance of prioritising action at the sou...

France - Agence Nationale du Médicament Vétérinaire

14-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to better equip consumers with nutritional information about dietary fiber in their food

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to better equip consumers with nutritional information about dietary fiber in their food

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to better equip consumers with nutritional information about dietary fiber in their food

FDA - U.S. Food and Drug Administration

31-5-2018

H-E-B Voluntarily Issues Recall Specific flavors and container sizes of EconoMax and Hill Country Fare ice creams and Creamy Creations sherbets recalled for broken metal in processing equipment

H-E-B Voluntarily Issues Recall Specific flavors and container sizes of EconoMax and Hill Country Fare ice creams and Creamy Creations sherbets recalled for broken metal in processing equipment

Committed to the quality of its products, H-E-B is voluntarily issuing an all-store recall for certain flavors and container sizes of EconoMax and Hill Country Fare ice creams and Creamy Creations sherbets for broken metal in processing equipment found during routine maintenance. The affected products were distributed to stores in Texas and Mexico.

FDA - U.S. Food and Drug Administration

21-10-2018

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%, up from 84% in 1995.

FDA - U.S. Food and Drug Administration

29-5-2018

EU/3/18/2021 (Chemo Research S.L.)

EU/3/18/2021 (Chemo Research S.L.)

EU/3/18/2021 (Active substance: Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin) - Orphan designation - Commission Decision (2018)3388 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/248/17

Europe -DG Health and Food Safety